Cargando…

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma

There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL). Bendamustine hydrochloride (bendamustine) has recently been approved for treatment of these patients. Bendamustine is a uniquely structured alkylating agent that lacks cross-res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aldoss, Ibrahim T, Blumel, Susan M, Bierman, Philip J
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004665/ https://www.ncbi.nlm.nih.gov/pubmed/21188134

Ejemplares similares

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma
por: Gil, Lidia, et al.
Publicado: (2014)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
por: Becker, M., et al.
Publicado: (2015)

Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study
por: Shi, Yuan-Kai, et al.
Publicado: (2021)

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
por: Cheson, Bruce D., et al.
Publicado: (2016)

Effects of chemotherapeutic agent bendamustine for non-hodgkin lymphoma on spermatogenesis in mice
por: Zang, Min-bo, et al.
Publicado: (2018)

BENDAMUSTINE: AN OLD DRUG IN THE NEW ERA FOR PATIENTS WITH NON-HODGKIN LYMPHOMAS AND CHRONIC LYMPHOCYTIC LEUKEMIA
por: Bogeljić Patekar, Martina, et al.
Publicado: (2018)

Immunotherapy in indolent Non-Hodgkin's Lymphoma
por: Amhaz, Ghid, et al.
Publicado: (2022)

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
por: Minson, Adrian, et al.
Publicado: (2022)

Role of antibody-based therapy in indolent non-Hodgkin's lymphoma
por: Willard, Patrick, et al.
Publicado: (2021)

The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas
por: Artemaki, Pinelopi I., et al.
Publicado: (2021)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2021)

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
por: Barrientos, Jacqueline C
Publicado: (2016)

Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience
por: Cerchione, Claudio, et al.
Publicado: (2016)

PB2080: EFFICACY AND SAFETY OF BENDAMUSTINE-BASED REGIMENS AS FIRST-LINE TREATMENT FOR INDOLENT B-CELL NON-HODGKIN LYMPHOMA: A PROSPECTIVE, MULTICENTER, REAL-WORLD STUDY IN CHINA
por: Li, S., et al.
Publicado: (2022)

Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
por: Pezzullo, Luca, et al.
Publicado: (2021)

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
por: Greenbaum, Adam M., et al.
Publicado: (2018)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Bendamustine-induced rash is associated with a favorable prognosis in patients with indolent B-cell lymphoma
por: Takahashi, Naoki, et al.
Publicado: (2021)

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma
por: Swoboda, Ryszard, et al.
Publicado: (2021)

Factors Impacting Treatment Decision Making in Older Adults With Indolent Non-Hodgkin Lymphoma
por: Trevino, Kelly, et al.
Publicado: (2021)

Increased plasma endostatin and GDF15 in indolent non-Hodgkin lymphoma
por: Hidman, Josefin, et al.
Publicado: (2023)

Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin's Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China
por: Zhang, Yujie, et al.
Publicado: (2022)

Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults
por: Harker-Murray, Paul, et al.
Publicado: (2023)

Role of bendamustine in the treatment of chronic lymphocytic leukemia
por: Jamshed, Saad, et al.
Publicado: (2009)

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
por: Saito, H, et al.
Publicado: (2015)

Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma
por: Saito, H, et al.
Publicado: (2017)

First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
por: Broccoli, A., et al.
Publicado: (2019)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin’s lymphoma: a monocenter analysis
por: Hadi, I., et al.
Publicado: (2021)

Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin’s Lymphoma
por: Fueger, Barbara J., et al.
Publicado: (2009)

Treatment of indolent lymphoma
por: Jeong, Seong Hyun
Publicado: (2022)

Non-Hodgkin's Lymphomas
por: Proctor, S.J.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_odjrbj7mp0ohvaegb28bci2srl